Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dan-DAPT trial
2022-500125-32-00Phase 4Authorised
- Sponsor
- Rigshospitalet
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of prasugrel, ticagrelor, aspirin and clopidogrel in myocardial infarction (MI) (2 arms), sponsored by Rigshospitalet. Primary endpoints: Net adverse clinical events (NACE) and BARC type 2-5 non-access site bleeding. Planned start Apr 2022; status: authorised.
02
Drugs
prasugrelticagreloraspirinclopidogrel
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2022-500125-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500125-32-00.